Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 5/20 | 0.45 |
| ▸ | CCR3 | P51677 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5345951 | 0.88 | SMN1; SMN2 (0.43) | SLC6A4SLC6A3SLC6A2HRH1CCR3 | |
| SCHEMBL5102799 | 0.86 | HRH1 (0.59) | SLC6A4SLC6A3SLC6A2HRH1CCR3 | |
| SCHEMBL5189696 | 0.80 | HRH1 (0.60) | HRH1CCR3KCNH2 | |
| SCHEMBL5335013 | 0.79 | SLC6A2 (0.44) | SLC6A4SLC6A3SLC6A2HRH1CCR3 | |
| SCHEMBL5335008 | 0.79 | SLC6A2 (0.44) | SLC6A4SLC6A3SLC6A2HRH1CCR3 | |
| SCHEMBL5335503 | 0.78 | CCR3 (0.43) | CCR3KDM4EALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5339660 | 0.78 | SLC6A2 (0.43) | SLC6A4SLC6A3SLC6A2HRH1CCR3 | |
| Hydrochloric Acid SCHEMBL5339666 | 0.78 | SLC6A2 (0.43) | SLC6A4SLC6A3SLC6A2HRH1CCR3 | |
| SCHEMBL5369447 | 0.77 | HRH1 (0.56) | SLC6A4SLC6A3SLC6A2HRH1CCR3 | |
| SCHEMBL13700880 | 0.77 | SLC6A2 (0.59) | SLC6A4SLC6A3SLC6A2HRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| EP-1487435-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003077907-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | SLC6A4 1121/4885SLC6A3 372/4885SLC6A2 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.